Newsfeeds - Spark Newswire

1 minute read

Alexion’s Ultomiris Sales Almost Doubles In 1H 2021 As $39B AstraZeneca Deal Looms

Today, 5:37 PM

Ultomiris, the successor to Alexion Pharmaceuticals Inc's (NASDAQ: ALXN) paroxysmal nocturnal hemoglobinuria (PNH) drug Soliris, is on track for another blockbuster year.

ALXN

3 minute read

Moderna Options Traders Mixed On S&P 500 Inclusion

By Melanie Schaffer

Today, 5:37 PM

Moderna, Inc (NASDAQ: MRNA) gapped up 6.64% Friday morning after it was announced the company will join the S&P 500 beginning July 21.

ALXN

1 minute read

Alexion’s Ultomiris Shows Compelling, Durable Efficacy In Rare Muscle Weakness Disorder

By Vandana Singh

Today, 5:37 PM

Alexion Pharmaceuticals Inc (NASDAQ:ALXN) announced topline results from a Phase 3 study evaluating Ultomiris (ravulizumab-cwvz) in adults with generalized myasthenia gravis…

ALXN

1 minute read

Why Moderna Shares Are Rallying Today

By Shanthi Rexaline

Today, 5:37 PM

Shares of COVID-19 vaccine company Moderna, Inc. (NASDAQ: MRNA), which ended Thursday's session with a market cap of $104.3 billion by virtue of a 5.28% rally, are seeing follow-through buying interest Friday.

ALXN

1 minute read

Hot
News

S&P Dow Jones Indices Announces Moderna To Join S&P 500, Will Replace Alexion

By Benzinga Newsdesk

Today, 5:37 PM

https://www.spglobal.com/spdji/en/documents/indexnews/announcements/20210715-1419561/1419561_5alxn.pdf

ALXN

5 minute read

Alexion Announces Phase 3 Study Of ULTOMIRIS In Generalized Myasthenia Gravis Met Its Primary Endpoint

By Bill Haddad

Today, 5:37 PM

– Study met primary endpoint of change from baseline in the Myasthenia Gravis-Activities of Daily Living Profile (MG-ADL) total score at Week 26 – – ULTOMIRIS demonstrated compelling

ALXN

6 minute read

The Daily Biotech Pulse: Galapagos Sinks On Data, J&J Recalls Sunscreen Products, FibroGen Awaits AdCom Verdict, 3 IPOs

By Shanthi Rexaline

Today, 5:37 PM

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 14)

ABCL

1 minute read

AstraZeneca Announced Receipt of Clearance from the European Commission for the Proposed Acquisition of Alexion

By Charles Gross

Today, 5:37 PM

AstraZeneca's (NYSE: AZN) proposed acquisition of Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) has achieved an important step towards completion by having cleared the European Commission review.

ALXN